Publicerat: 2022-10-21 09:54:22
Updated with new link.
Curasight, a Danish biotech company with two core radiopharmaceutical products, is expanding into two new indications for its two new modalities. Following a change in analyst, we update our valuation range and explore the opportunities for Curasight, and how it can leverage its strong technical platform and unique targeting of the uPAR receptor. We set our new mid-point value at SEK 54 per share.
Länk till analysen